Opendata, web and dolomites


First effective targeted therapy for T-cell acute lymphoblastic leukemia (T-ALL) and other NOTCH pathway driven cancers

Total Cost €


EC-Contrib. €






 CB-103 project word cloud

Explore the words cloud of the CB-103 project. It provides you a very rough idea of what is the project "CB-103" about.

efficiency    median    treatment    compound    healthy    75    bone    marrow    benefit    afflicted    colorectal    children    ones    survival    adverse    14    off    lymphoblastic    breast    supply    drive    rates    stopping    index    cell    small    lung    blocks    establishing    model    expansion    answer    blood    250    chain    drugs    cellestia    trials    dlt    found    relative    accounts    forms    25    toxicity    additionally    business       chemotherapy    issue    dose    molecule    stem    tumorigenesis    stage    tumor    acute    significantly    care    improvement    therapeutic    cure    discriminate    cancer    toxicological    progression    103    cb    too    reduce    cells    activated    total    inhibiting    dependent    signaling    people    commercialization    scalable    cancers    aged    roles    oncogenic    standard    collaborations    limiting    ineffective    play    complete    planning    drug    transcription    conventional    downstream    thanks    leukemia    cancerous    prolongs    strategy    notch    killing    indicate    aggressive    clinical    verifying    roots   

Project "CB-103" data sheet

The following table provides information about the project.


Organization address
city: Basel
postcode: CH 4057
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLESTIA BIOTECH AG CH (Basel) coordinator 50˙000.00


 Project objective

T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive NOTCH-dependent cancer that affects the blood and bone marrow especially in children aged 0-14 years, and currently has no effective cure. T-ALL accounts for about 25% of the total cases of Lymphoblastic Leukemia (ALL); additionally, an estimated 250,000 people are afflicted by NOTCH-dependent cancers every year. Chemotherapy, the standard-of-care treatment for T-ALL, can reduce tumor growth, but it is ineffective at killing the cancer stem cells that drive tumor progression. Moreover, it can lead to adverse toxicological effects as a result of off-target toxicity, as the drug cannot discriminate between healthy and cancerous cells. Small molecule drugs help to solve this issue thanks to their high efficiency in targeting tumor cells. Cellestia may have found the answer. Its novel approach targets a tumor development pathway, the NOTCH, which play crucial oncogenic roles in tumorigenesis, tumor expansion and survival. By inhibiting the NOTCH signaling in its most downstream part, Cellestia’s small molecule compound, CB-103, blocks the problem at the roots (i.e. specifically at the level of the NOTCH transcription complex) stopping cancer cells growth and survival. Pre-clinical results show CB-103 to have a high therapeutic index relative to conventional cancer drugs. Most importantly, it significantly prolongs survival rates (median improvement of 75%) with no adverse side effects or dose-limiting toxicity (DLT). Results indicate it may have benefit for other cancers too – any in which NOTCH pathway is highly activated, including forms of leukemia and other cancers such as lung, breast and colorectal. The Phase 1 project will be focused on establishing a complete and scalable supply chain, verifying the business model and commercialization strategy, planning new collaborations and partnerships, including the ones to implement the next clinical trials stage.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CB-103" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CB-103" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Presque (2019)

Smart Nursing Bra

Read More  

HUD (2018)


Read More